• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    2/16/24 12:31:13 PM ET
    $AMN
    $APLT
    $CCRN
    $HCTI
    Professional Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMN alert in real time by email

    Gainers

    • OneMedNet (NASDAQ:ONMD) shares rose 91.2% to $1.44 during Friday's regular session. The market value of their outstanding shares is at $46.4 million.
    • Applied Therapeutics (NASDAQ:APLT) stock increased by 28.53% to $4.82. The market value of their outstanding shares is at $372.2 million.
    • Modular Medical (NASDAQ:MODD) stock moved upwards by 24.58% to $1.56. The company's market cap stands at $34.2 million. As per the press release, Q3 earnings came out 3 days ago.
    • Prelude Therapeutics (NASDAQ:PRLD) shares moved upwards by 23.27% to $4.29. The company's market cap stands at $235.2 million.
    • Ocugen (NASDAQ:OCGN) shares rose 21.98% to $0.91. The company's market cap stands at $233.4 million.
    • Phathom Pharmaceuticals (NASDAQ:PHAT) shares moved upwards by 19.56% to $8.25. The company's market cap stands at $472.3 million.

    Losers

    • AMN Healthcare Services (NYSE:AMN) shares declined by 18.9% to $63.0 during Friday's regular session. The company's market cap stands at $2.3 billion. The company's, Q4 earnings came out yesterday.
    • Cross Country Healthcare (NASDAQ:CCRN) stock declined by 14.52% to $18.16. The market value of their outstanding shares is at $638.5 million.
    • Inventiva (NASDAQ:IVA) stock decreased by 13.02% to $3.43. The market value of their outstanding shares is at $176.9 million.
    • Healthcare Triangle (NASDAQ:HCTI) shares declined by 11.84% to $2.4. The company's market cap stands at $10.3 million.
    • T2 Biosystems (NASDAQ:TTOO) shares decreased by 11.74% to $5.64. The market value of their outstanding shares is at $22.8 million. As per the press release, Q4 earnings came out yesterday.
    • Pacific Biosciences (NASDAQ:PACB) shares declined by 11.63% to $5.89. The market value of their outstanding shares is at $1.5 billion. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMN
    $APLT
    $CCRN
    $HCTI

    CompanyDatePrice TargetRatingAnalyst
    Pacific Biosciences of California Inc.
    $PACB
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    Cross Country Healthcare Inc.
    $CCRN
    3/5/2026$14.00Hold → Buy
    The Benchmark Company
    Cross Country Healthcare Inc.
    $CCRN
    2/3/2026$11.00Neutral
    Wedbush
    Inventiva S.A.
    $IVA
    1/28/2026$18.00Overweight
    Barclays
    Inventiva S.A.
    $IVA
    1/12/2026$12.00Outperform
    Leerink Partners
    Inventiva S.A.
    $IVA
    1/7/2026$12.00Buy
    UBS
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    More analyst ratings

    $AMN
    $APLT
    $CCRN
    $HCTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cash W Larry bought $40,829 worth of shares (5,000 units at $8.17), increasing direct ownership by 3% to 204,632 units (SEC Form 4)

    4 - CROSS COUNTRY HEALTHCARE INC (0001141103) (Issuer)

    12/9/25 4:08:59 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Chief Medical Officer Yu Jeffrey converted options into 2,307,549 shares, bought $959,586 worth of shares (2,010,479 units at $0.48) and was granted 245,000 shares, increasing direct ownership by 165% to 7,326,223 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:56:08 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Medical Officer Yu Jeffrey bought $8,929 worth of shares (9,540 units at $0.94) and was granted 230,769 shares, increasing direct ownership by 10% to 2,763,195 units (SEC Form 4)

    4 - OneMedNet Corp (0001849380) (Issuer)

    11/26/25 9:55:32 PM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AMN
    $APLT
    $CCRN
    $HCTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cross Country Healthcare and Open Hearts for Orphans Announce Community Partnership to Strengthen Families and Support Vulnerable Children

    Cross Country Healthcare, Inc. (NASDAQ:CCRN), a technology-driven healthcare workforce solutions company delivering an AI-powered digital platform and advisory services backed by nearly 40 years of healthcare labor expertise, today announced a new community partnership with Open Hearts for Orphans (OHFO), a South Florida nonprofit dedicated to providing hope, healing, and family for orphaned and vulnerable children. This partnership brings together two mission-driven organizations committed to strengthening families, supporting communities, and improving outcomes for vulnerable children and the caregivers who support them. Through this collaboration, Cross Country will support OHFO thro

    3/10/26 7:30:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

    Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 Preclinical development and IND enabling studies for PRT13722, highly-selective oral KAT6A degrader underway, and the Company intends to file the IND for PRT13722 in mid-2026 with Phase 1 study initiation anticipated in the 2nd half of 2026 Current cash runway expected into second quarter of 2027 with $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025  WILMINGTON, Del., March

    3/10/26 7:01:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMN
    $APLT
    $CCRN
    $HCTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pacific Biosciences downgraded by Barclays with a new price target

    Barclays downgraded Pacific Biosciences from Equal Weight to Underweight and set a new price target of $1.50

    3/6/26 8:26:02 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Cross Country upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Cross Country from Hold to Buy and set a new price target of $14.00

    3/5/26 8:22:11 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    Wedbush initiated coverage on Cross Country with a new price target

    Wedbush initiated coverage of Cross Country with a rating of Neutral and set a new price target of $11.00

    2/3/26 8:08:13 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $AMN
    $APLT
    $CCRN
    $HCTI
    SEC Filings

    View All

    Cross Country Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CROSS COUNTRY HEALTHCARE INC (0001141103) (Filer)

    3/10/26 4:12:04 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    SEC Form S-8 filed by Prelude Therapeutics Incorporated

    S-8 - Prelude Therapeutics Inc (0001678660) (Filer)

    3/10/26 8:40:57 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Prelude Therapeutics Incorporated

    10-K - Prelude Therapeutics Inc (0001678660) (Filer)

    3/10/26 8:24:31 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMN
    $APLT
    $CCRN
    $HCTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Johnson-Greene Treerita Essalima claimed ownership of 500,350 shares (SEC Form 3)

    3 - Ocugen, Inc. (0001372299) (Issuer)

    3/5/26 9:27:38 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gibson Christopher was granted 53,913 shares (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:43:24 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Gibson Christopher

    3 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:39:25 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AMN
    $APLT
    $CCRN
    $HCTI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMN
    $APLT
    $CCRN
    $HCTI
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cross Country Healthcare Announces CEO Transition

    Co-Founder and Chairman, Kevin C. Clark, Returns as Chief Executive Officer Cross Country Healthcare, Inc. (the "Company" and "Cross Country") (NASDAQ:CCRN) today announced that John A. Martins, the Company's President and Chief Executive Officer, has separated from the Company and ceased to serve as a member of its Board of Directors (the "Board"), effective as of December 14, 2025. The Board appointed Kevin C. Clark, the Company's current Chairman, former Chief Executive Officer, and Co-Founder, to succeed Mr. Martins as the Company's President and Chief Executive Officer. Mr. Clark will continue to serve as the Chairman of the Board. "The Board members are thrilled to have Kevin return

    12/15/25 8:15:00 AM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    $AMN
    $APLT
    $CCRN
    $HCTI
    Financials

    Live finance-specific insights

    View All

    Cross Country Healthcare Announces Fourth Quarter and Full Year 2025 Financial Results

    Cross Country Healthcare, Inc. (the "Company," "Cross Country," "we," "us," and "our") (NASDAQ:CCRN) today announced financial results for its fourth quarter and full year ended December 31, 2025. SELECTED FINANCIAL INFORMATION: Dollars are in thousands, except per share amounts Q4 2025 Variance Q4 2025 vs Q4 2024 Variance Q4 2025 vs Q3 2025 Full Year 2025 Variance 2025 vs 2024 Revenue $ 236,761       (24 ) %   (5 ) % $ 1,054,293       (22 ) % Gross profit margin*   20.3   %   30

    3/4/26 4:15:00 PM ET
    $CCRN
    Professional Services
    Consumer Discretionary

    UPDATE – AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

    Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross profit$195.1(11%)$774.1(16%)Net income (loss)($7.7)nm($95.7)nmDiluted earnings (loss) per share($0.20)nm($2.48)nmAdjusted diluted EPS*$0.22(70%)$1.36(59%)Adjusted EBITDA*$

    2/19/26 8:13:45 PM ET
    $AMN
    Professional Services
    Consumer Discretionary

    AMN Healthcare Announces Fourth Quarter and Full Year 2025 Results

    Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025% ChangeQ4 2024Full Year2025% ChangeFull Year2024Revenue$748.22%$2,730.4(8%)Gross profit$195.1(11%)$774.1(16%)Net income (loss)($7.7)nm($95.7)nmDiluted earnings (loss) per share($0.20)nm($2.48)nmAdjusted diluted EPS*$0.22(70%)$1.36(59%)Adjusted EBITDA*$

    2/19/26 4:15:00 PM ET
    $AMN
    Professional Services
    Consumer Discretionary

    $AMN
    $APLT
    $CCRN
    $HCTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials